


1/14



300 Base pair

The PAX2 expression in 3 out of 5 channel TURP specimens.


- Lane 1 negative control (water)
- Lane 2-6 channel TURPs (i.e. prostate cancers)
- Lane 7 positive control (OUK 117)

- blank lanes

*Fig. 1(a)*

2/14

## GAPDH Expression in the 5 Channel TURPs




Lane 1-5 Channel TURP 1 to 5  
 Lane 7 Negative control (water)  
 Lanes - Blank

**Fig. 1(b)**

Lack of expression of PAX 2 in 10 Benign Prostatic Hypertrophy specimens

3/14




Lanes 1-10: the 10 benign prostatic hypertrophy specimens  
 lane 12: Positive control (UOK 117)  
 Lane 14: negative control (water)  
 Lanes - Blank

**Fig. 2(a)**

# GAPDH RTPCR of the 10 Benign Prostatic Hypertrophy specimens

4/14




Lanes 1-10: Ten Benign samples  
 Lane 11: Negative control (water)  
 Lanes 12: Blank lanes

**Fig. 2(b)**

5/14

300 base pair

**Expression of PAX 2 in cell lines**


Lane 1 LNCaP  
Lane 2 DU145  
Lane 3 PC3  
Lane 4 negative control (water)  
Lane 5 UOK 231  
Lane 6 UOK 117

- blank lanes

***Fig. 3(a)***

6/14

## GAPDH RTPCR of the Cell Lines



Lane 1: LNCaP  
Lane 2: DU145  
Lane 3: PC3  
Lanes -: Blank  
Lane 5: Negative Control (water)

***Fig. 3(b)***

# Expression of PAX2 in tumours 1,3,7,14,16,19,21,25,26.



The Lanes are marked with the number given to each tumour. UOK117 is the positive control. Water is the negative control.




Southern hybridisation  
of the above gel

*Fig. 4(a)*

8/14

Expression of PAX2 in tumours 24,27,32,38,41 and 43.




The Lanes are marked with the number given to each tumour. UOK117 is the positive control. Water is the negative control.

**Fig. 4(b)**



# GAPDH expression in tumours 24,27,32,38,41 and 43


9/14




200 Base pair

The Lanes are marked with the number given to each tumour.  
Water is the negative control.

**Fig. 4(c)**

**Fig. 5A**

11/14

**Fig. 5B**

# PAX2 Expression in Prostate Cancer

H20  
UOK117


## 27 Prostate Cancers

## PAX2


- 14/27 ( 52%) of prostate cancers express PAX2

**Fig. 5A3**

13/14

*Fig. 5C*

14/14

**Fig. 5D**

SUBSTITUTE SHEET (RULE 26)